Roche gains label expansion for heart attack medicine TNKase to treat acute ischemic stroke
Over nearly the last three decades, Genentech has had the lone medicine on the market for stroke. On Monday, the Roche subsidiary added a second stroke treatment to its repertoire, gaining an FDA endorsement for TNKase.
Over nearly the last three decades, Genentech has had the lone medicine on the market for stroke. On Monday, the Roche subsidiary added a second stroke treatment to its repertoire, gaining an FDA endorsement for TNKase.
